The verdicts in South Carolina, Louisiana, Texas, and now Arkansas against JNJ/Janssen are beginning to mount and may reach the magnitude that begins to have a preventive effect. I expect the KOL set will see these verdicts as driving Pharma away from what they call "CNS," though that’s unlikely the cause. They’ve milked the market and are moving on. It’s pretty simple. I expect the inertia of motion will continue the medication focus of many of the set of psychiatrists who’ve known little else in their careers, but the evaporation of huge sums of pharmaceutical money should at least take some of the fire out of the movement.
The effects of child abuse and neglect on cognitive functioning in adulthood
by Felicia Goulda, Jennifer Clarke a,b, Christine Heim c, Philip D. Harvey a, Matthias Majer c, and Charles B. Nemeroff aa Department of Psychiatry and Behavioral Sciences, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USAb Department of Epidemiology and Public Health, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USAc Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USAJournal of Psychiatric Research 2012 46:500-506.
AIMS: Recent research has revealed that early life trauma (ELS), including abuse (sexual and/or physical) and neglect, produce lasting changes in the CNS. We posited that cognitive deficits, often observed in psychiatric patients, result, in part, due to the neurobiological consequences of ELS. Additionally, we hypothesized that the nature and magnitude of cognitive deficits would differ according to the subtype of ELS experienced.
METHOD: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess neurocognitive functioning in 93 subjects (60 with ELS and 33 without). In the patients with a history of ELS, 35% and 16.7%, respectively, met criteria for current major depression and PTSD.
RESULTS: Significant associations between ELS status and CANTAB measures of memory and executive and emotional functioning were found.
CONCLUSIONS: These data suggest that exposure to ELS results in a cascade of neurobiological changes associated with cognitive deficits in adulthood that vary according to the type of trauma experienced.
Funding body:
Support for this research was provided by a National Institute of Mental Health grant, MH-58922, which was awarded to Dr. Nemeroff.
Contributors:
All contributors are listed as authors. Drs. Nemeroff and Heim designed the study and wrote the protocol. Dr. Heim conducted the study. Dr. Majer collected data for the study. Dr. Gould managed the literature searches and analyses. Dr. Clark performed the data analyses. Dr. Gould wrote the first draft of the manuscript with Drs. Nemeroff and Harvey. All authors provided editorial contributions to the paper.
YEAR | AMOUNT |
2000 | $6,219,622.00 |
2001 | $6,263,166.00 |
2002 | $6,413,344.00 |
2003 | $7,234,250.00 |
2004 | $2,972,156.00 |
2005 | $3,709,165.00 |
2006 | $7,904,831.00 |
2007 | $6,816,202.00 |
TOTAL | $47,532,736.00 |
I looked up Nemeroff in the NIH RePORTER database and tallied the net grant amount from 2000 when they started posting amounts to his last listing in 2007. I knew it was a lot, but the actual figure caused me to gasp. I’m sure that there’s some kind of creative accounting that explains how an expired NIMH Grant was involved in this study of people who read the ads in the Atlanta Journal Constitution and ride MARTA buses, but whatever the method – it doesn’t change the fact that what we got for our $47 M was not useful science. And I expect the pharmaceutical grant contributions to Emory in those years would also illicit a gasp response.
Troubling has been the popular press’s coverage of the concept that early age depression leads to latter life health problems. The take away from pharma will be that we should all be on antidepressants for our general health.
This may seem like a reach until, from my perspective, you look at the push to diagnose two year olds as bi-polar and statins have been associated with curing all types of diseases, including dementia.
In the recent past many doctors gave statins as a matter of course to all of their patients, because they were “good†for you. As these drugs have gone off patient the push has lessened as drug money has stopped flowing to promote their use.
Can we now expect any less of a promotion of anti-depressant from pharma?
Steve Lucas
http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=1096598
APF Convenes Unique Pipeline Summit
“Leaders from academia, government, the pharmaceutical industry, venture-capital firms, and clinicians met at APA headquarters March 8 to discuss the shrinking investment in new drug development for psychiatric disorders.”
“One of APF and APA’s roles, Schatzberg said, is to continue to fight the stigma against psychiatry and psychiatric drugs. In addition to facilitating more collaboration between the government and the private sector, he proposed that APF and APA work with other stakeholders to create incentives for industry to reinvest in psychiatry. Philip Skolnick, D.Sc., Ph.D., of NIDA raised the issue of whether extending market exclusivity for compounds that are first in class and/or first in indication as is done abroad could promote investment.”